Back to Journals » Therapeutics and Clinical Risk Management » Volume 10

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir

Authors Kanda T, Nakamoto S, Wu S, Yokosuka O

Received 13 February 2014

Accepted for publication 31 March 2014

Published 24 May 2014 Volume 2014:10 Pages 387—394


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Tatsuo Kanda, Shingo Nakamoto, Shuang Wu, Osamu Yokosuka

Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan

Abstract: Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepatocellular carcinoma. In the USA, Canada, and Japan, simeprevir – one of the second-generation HCV NS3/4A protease inhibitors – in combination with peginterferon α-2a or 2b plus ribavirin has recently been approved for HCV genotype 1-infected patients and is now used in daily clinical practice. This review summarizes the mechanism of action of simeprevir and the results of clinical trials of simeprevir and peginterferon plus ribavirin for HCV genotype 1 patients. In general, the simeprevir and peginterferon plus ribavirin treatment is highly effective and its adverse events are similar to those of peginterferon plus ribavirin only, the exception being milder, reversible jaundice. In the near future, the development of interferon-free regimens with simeprevir is expected. Careful attention should be paid to new results of clinical trials with simeprevir.

Keywords: hepatitis C virus, HCV NS3/4A protease inhibitor, hepatocellular carcinoma, TMC435

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]